Marston E, Weston V, Jesson J, Maina E, McConville C, Agathanggelou A, Skowronska A, Mapp K, Sameith K, Powell JE, Lawson S, Kearns P, Falciani F, Taylor M, Stankovic T. (2009) Stratification of paediatric ALL by in vitro cellular responses to DNA double strand breaks provides insight into the molecular mechanisms underlying clinical response Blood. 113(1):117-26.
Stewart GS, PanierS, TownsendK, Al-HakimA, KolasNK, MillerES, NakadaS, YlankoJ, OlivariusS, MendezM, TagliaferroA, PelletierL, TaubenheimN, DurandyA, Byrd PJ, StankovicT, TaylorAMR, Durocher D. (2009) The gene mutated in the RIDDLE syndrome regulates an ubiquitin-dependent signalling cascade at sites of DNA damage. Cell; 136:420-34.
Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJS, Smith G, Powell JE, Taylor AMR, Moss PAH, Stankovic T (2010). The PARP inhibitor olaparib suppresses growth of ATM mutant lymphoid tumour cells in vitro and in vivo. Blood;116(22):4578-87
Anna Skowronska, Anton Parker, Gulshanara Ahmed, Ceri Oldreive, Zadie Davis, Sue Richards, Martin Dyer, Estella Matutes E, David Gonzalez, AMR Taylor, Paul Moss, David Oscier, Tatjana Stankovic. Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on UK CLL4 Trial. JCO 2012;30(36):4524-32.
Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, Zlatanou A, Oldreive C, Wei W, Stewart G, Longman J, Smith E, Kearns P, Knapp S, Stankovic T. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013 Jul 19;3:e126
Ceri E. Oldreive,Anna Skowronska, Nicholas J. Davies, Helen Parry, Angelo Agathanggelou, Sergey Krysov, Graham Packham, Zbigniew Rudzki, Guy Pratt, A. Malcolm R. Taylor, Paul Moss, and Tatjana Stankovic. T-cell numbers and subtypes control the duration and utility of primary chronic lymphocytic leukaemia xenograft in alymphoid mice, Disease Models, Mechanisms 2015 Nov 1;8(11):1401-12
Angelo Agathanggelou, Victoria J. Weston, Tracey Perry, Nicholas J. Davies, Anna Skowronska, Daniel T. Payne, John S. Fossey, Ceri E. Oldreive, Wenbin Wei, Guy Pratt, Helen Parry, David Oscier, Steve J. Coles, Paul S. Hole, Richard L. Darley, Michael McMahon, John D. Hayes, Paul Moss, Grant Stewart, A. Malcolm R. Taylor and Tatjana Stankovic. Targeting the ATM-null phenotype in chronic lymphocytic leukemia with pro-oxidants 1. Haematologica 2015 Aug;100(8):1076-85
Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells. Blood. 2016 Feb 4;127(5):582-95
View all publications in research portal